Log in

aTyr Pharma Stock Forecast, Price & News

-0.14 (-3.64 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $3.71
50-Day Range
MA: $3.99
52-Week Range
Now: $3.71
Volume88,964 shs
Average Volume211,051 shs
Market Capitalization$35.38 million
P/E RatioN/A
Dividend YieldN/A
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.
Read More
aTyr Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
Current SymbolNASDAQ:LIFE



Sales & Book Value

Annual Sales$420,000.00
Book Value$5.40 per share


Net Income$-23,600,000.00
Net Margins-190.06%


Market Cap$35.38 million
Next Earnings Date11/12/2020 (Estimated)
-0.14 (-3.64 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

How has aTyr Pharma's stock price been impacted by Coronavirus?

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LIFE stock has increased by 22.4% and is now trading at $3.71.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of aTyr Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for aTyr Pharma

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for aTyr Pharma

How were aTyr Pharma's earnings last quarter?

aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings results on Thursday, August, 13th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.04. aTyr Pharma had a negative return on equity of 51.92% and a negative net margin of 190.06%.
View aTyr Pharma's earnings history

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

aTyr Pharma's stock reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for LIFE?

3 brokerages have issued 1 year target prices for aTyr Pharma's shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate aTyr Pharma's share price to reach $12.00 in the next year. This suggests a possible upside of 223.5% from the stock's current price.
View analysts' price targets for aTyr Pharma

Who are some of aTyr Pharma's key competitors?

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), SCYNEXIS (SCYX), Biocept (BIOC), Idera Pharmaceuticals (IDRA), Fulcrum Therapeutics (FULC), NVIDIA (NVDA), Precigen (PGEN), QUALCOMM (QCOM), Viking Therapeutics (VKTX) and VIVUS (VVUS).

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the following people:
  • Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
  • Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)
  • Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
  • Dr. David J. King, Scientific Consultant (Age 60)
  • Xiang-Lei Yang Ph.D., Founder

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (7.76%) and Two Sigma Advisers LP (0.85%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John K Clarke, John Mendlein, Nancy Krueger, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends for aTyr Pharma

Which major investors are selling aTyr Pharma stock?

LIFE stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..
View insider buying and selling activity for aTyr Pharma

Which major investors are buying aTyr Pharma stock?

LIFE stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein, Paul Schimmel, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $3.71.

How big of a company is aTyr Pharma?

aTyr Pharma has a market capitalization of $35.38 million and generates $420,000.00 in revenue each year. The biotechnology company earns $-23,600,000.00 in net income (profit) each year or ($7.03) on an earnings per share basis. aTyr Pharma employs 42 workers across the globe.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is www.atyrpharma.com.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.